Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Alberto A. Chiappori

Dr. Alberto A. Chiappori

Medical Oncologist

Dr. Alberto Chiappori is a medical oncologist who treats lung cancer and malignant pleural mesothelioma at the H. Lee Moffitt Cancer Center in Tampa, Florida.

Get in touch
Jump to a Topic:

About Alberto A. Chiappori

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Board Certified icon

    Board Certified in Medical Oncology

  • Immunotherapy icon


  • Works for Specialty Center icon

    Works for Specialty Center

As senior member of Moffitt’s Thoracic Oncology Program, Chiappori is the primary investigator in several clinical trials, including three involving pleural mesothelioma patients and treatment research.

One of those trials is exploring the use of Opdivo (nivalumab) and Cyramza (ramucirumab), a novel immunotherapy combination that has the potential to significantly change the way mesothelioma is treated.

The trial is aimed at patients whose tumors have progressed after chemotherapy.

A second mesothelioma trial is a toxicity study for patients who undergo pleurectomy and decortication surgery, along with adjuvant chemotherapy and radiation therapy.

The third clinical trial is studying the effect of the Alimta (pemetrexed) and cisplatin chemotherapy combination for patients with a low expression of the enzyme argininosuccinate synthetase 1.

Respected for His Clinical Research

Chiappori has been at Moffitt’s Thoracic Oncology Program since 2001, serving patients and authoring numerous reports in respected medical publications.

Those include Clinical Cancer Research, Journal of Clinical Oncology and Journal of Thoracic Oncology.

Chiappori received his medical degree from the Universidad Peruana Heredia in Lima, Peru.

He did his residency at Southern Illinois University School of Medicine and his fellowship at Vanderbilt University School of Medicine.

As the lead investigator of another study, he presented his findings in 2018 at the Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

He was lauded for his work that demonstrated the effectiveness of another immunotherapy combination for advanced non-small cell lung cancer.

Works Closely with Other Mesothelioma Specialists

At Moffitt, Chiappori works closely with thoracic surgeon Dr. Jacques Fontaine, director of the Mesothelioma Research and Treatment Center.

Moffitt’s program includes a wealth of experience in treating mesothelioma, the rare and aggressive cancer caused by exposure to asbestos.

Oncologists, radiologists, pathologists, surgeons and supportive-care providers meet regularly to discuss each case, providing a personalization to care that is tough to match.

The center is known for its expertise in treating all forms of mesothelioma and its multidisciplinary approach to therapy.

Learn More About Mesothelioma Treatment in Florida

Disclaimer: Dr. Alberto A. Chiappori has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Matt Mauney, Content Writer at
Edited by

2 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Moffitt Cancer Center. (n.d.). Alberto A. Chiappori, MD.
    Retrieved from:
  2. Ecco-The European Cancer Organization. (2018, November 14). Combination of two immunotherapies show activity in non-small cell lung cancer patients. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified July 24, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now